Akari Therapeutics(AKTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Existing Investors Support the Company with Issuance of $1 Million in Unsecured Convertible Notes Secured $7.6 Million in Upsized Financing Round Receives Positive a ...